Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MGUUX
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
FDA-022
|
|||||
| Synonyms |
FDA 022; FDA-022; FDA022
Click to Show/Hide
|
|||||
| Organization |
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2)
|
Antigen Info | ||||
| Payload Name |
DX-8951 derivative (DXd)
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Val-Ala-PABC double self-immolative linker
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
BB05
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05564858 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase study to evaluate the safety, tolerability, pharmacokinetics and efficacy of FDA022-BB05 in subjects with advanced solid malignant tumors. | ||||
References